drugset / Trial / NCT00204074

Treatment of Menstrual Migraine With Sequential, Transdermal, 17-Beta-Estradiol. A Double-Blind, Randomised, Cross-Over Trial.

NCT00204074

RandomizedCrossoverDouble-blindTreatment

Summary

The purpose of this study is to determine whether transdermally administered 17-beta estradiol sequentially could reduce the number of, and severity of, menstrual migraine attacks.

Timeline

Start
2001-10
Primary completion
Completion
2005-07

Drugs

EvaluationDrugModalityDoseRoute
Subject 17-beta estradiol Unknown 100 ug Other

Indications